Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer

Clin Lung Cancer. 2017 May;18(3):e211-e213. doi: 10.1016/j.cllc.2016.11.001. Epub 2016 Nov 11.

Authors

Leah M Pervere¹, Sagar Rakshit², Alexa B Schrock¹, Vincent A Miller¹, Siraj M Ali¹, Vamsidhar Velcheti³

Affiliations

¹ Foundation Medicine, Inc, Cambridge, MA.
² Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH.
³ Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. Electronic address: velchev@ccf.org.

PMID: 28024926
DOI: 10.1016/j.cllc.2016.11.001

No abstract available

Keywords: BRAF inhibitor; Comprehensive genomic profiling; Kinase; MEK; NSCLC.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
DNA Mutational Analysis
Female
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
MAP Kinase Kinase Kinases / antagonists & inhibitors
Middle Aged
Molecular Targeted Therapy
Mutation / genetics*
Neoplasm Staging
Oximes / pharmacology
Oximes / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Pyridones / pharmacology
Pyridones / therapeutic use*
Pyrimidinones / pharmacology
Pyrimidinones / therapeutic use*
Remission Induction

Substances

Imidazoles
Oximes
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase Kinases
dabrafenib